Celgene, Nurix Collaborate For $150m Up Front

Celgene will pay Nurix Inc. $150m up front to develop and commercialize novel small molecules that modulate the ubiquitin proteasome system (UPS) in a deal that gives both companies multiple options for benefitting from joint oncology, inflammation and immunology programs.